These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21677543)

  • 1. A case of hairy cell leukemia with CCND1-IGH@ translocation: indolent non-nodal mantle cell lymphoma revisited.
    Chen D; Ketterling RP; Hanson CA; Colgan JP; Zent CS; Viswanatha DS
    Am J Surg Pathol; 2011 Jul; 35(7):1080-4. PubMed ID: 21677543
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-multiple lymphomatous polyposis form of mantle cell lymphoma in the gastrointestinal tract.
    Tamura S; Ohkawauchi K; Yokoyama Y; Higashidani Y; Daibata M; Hiroi M; Yamamori S; Onishi S
    J Gastroenterol; 2004 Oct; 39(10):995-1000. PubMed ID: 15549454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD5-undetected by immunohistochemistry, t(11;14)(q13;q32)-positive conjunctival mantle cell lymphoma: a case report.
    Yoo SB; Kim YA; Jeon YK; Kim CW
    Pathol Res Pract; 2008; 204(10):779-83. PubMed ID: 18572329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of t(12;14)(p13;q32) in a patient with IGH-CCND1 negative mantle cell lymphoma resembling ultra-high risk chronic lymphocytic leukemia.
    Miao Y; Wang R; Fan L; Qiu H; Wu Y; Chen Y; Xu W; Li J
    Int J Clin Exp Pathol; 2015; 8(6):7494-8. PubMed ID: 26261659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
    Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
    J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination chemotherapy followed by an immunotoxin (anti-B4-blocked ricin) in patients with indolent lymphoma: results of a phase II study.
    Longo DL; Duffey PL; Gribben JG; Jaffe ES; Curti BD; Gause BL; Janik JE; Braman VM; Esseltine D; Wilson WH; Kaufman D; Wittes RE; Nadler LM; Urba WJ
    Cancer J; 2000; 6(3):146-50. PubMed ID: 10882329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A patient with mantle cell lymphoma who successfully underwent auto-PBSCT in combination with in vivo purging of tumor cells using rituximab].
    Kanaji N; Ishibashi K; Uno H; Hino N
    Gan To Kagaku Ryoho; 2002 Dec; 29(13):2569-72. PubMed ID: 12506485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid detection of the t(11;14) translocation in mantle cell lymphoma by interphase fluorescence in situ hybridization on archival cytopathologic material.
    Bentz JS; Rowe LR; Anderson SR; Gupta PK; McGrath CM
    Cancer; 2004 Apr; 102(2):124-31. PubMed ID: 15098257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Disappearance of CD 20 after treatment with rituximab of mantle cell lymphoma].
    Yoshida K; Kayano H; Shimada T; Wakao D; Takahashi N; Sugahara Y; Yagasaki F; Ito Y; Kawai N; Matsuda A; Suzuki T; Bessho M
    Rinsho Ketsueki; 2003 Mar; 44(3):174-81. PubMed ID: 12722344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia.
    Miranda RN; Briggs RC; Kinney MC; Veno PA; Hammer RD; Cousar JB
    Mod Pathol; 2000 Dec; 13(12):1308-14. PubMed ID: 11144927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amplification of IGH/CCND1 fusion gene in a primary plasma cell leukemia case.
    Ishigaki T; Sasaki K; Watanabe K; Nakamura N; Toyota S; Kobayashi H; Tohda S
    Cancer Genet Cytogenet; 2010 Aug; 201(1):62-5. PubMed ID: 20633772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blastoid and common variants of mantle cell lymphoma exhibit distinct immunophenotypic and interphase FISH features.
    Parrens M; Belaud-Rotureau MA; Fitoussi O; Carerre N; Bouabdallah K; Marit G; Dubus P; de Mascarel A; Merlio JP
    Histopathology; 2006 Mar; 48(4):353-62. PubMed ID: 16487357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
    Ladetto M; Magni M; Pagliano G; De Marco F; Drandi D; Ricca I; Astolfi M; Matteucci P; Guidetti A; Mantoan B; Bodoni CL; Zanni M; Boccadoro M; Gianni AM; Tarella C
    Biol Blood Marrow Transplant; 2006 Dec; 12(12):1270-6. PubMed ID: 17162208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclin D1 (CCND1) messenger RNA expression as assessed by real-time PCR contributes to diagnosis and follow-up control in patients with mantle cell lymphoma.
    Bacher U; Kern W; Haferlach C; Alpermann T; Haferlach T; Schnittger S
    Exp Hematol; 2013 Dec; 41(12):1028-37. PubMed ID: 24060591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathogenesis of mantle cell lymphoma: new perspectives and challenges with clinical implications.
    Navarro A; Royo C; Hernández L; Jares P; Campo E
    Semin Hematol; 2011 Jul; 48(3):155-65. PubMed ID: 21782057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current treatment approaches for mantle-cell lymphoma.
    Witzig TE
    J Clin Oncol; 2005 Sep; 23(26):6409-14. PubMed ID: 16155027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma.
    Robak T; Smolewski P; Cebula B; Szmigielska-Kaplon A; Chojnowski K; Blonski JZ
    Cancer; 2006 Oct; 107(7):1542-50. PubMed ID: 16948126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunophenotypic variations in mantle cell lymphoma.
    Gao J; Peterson L; Nelson B; Goolsby C; Chen YH
    Am J Clin Pathol; 2009 Nov; 132(5):699-706. PubMed ID: 19846810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mantle cell lymphoma in the ocular adnexal region.
    Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
    Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.